FIELD: medicine.
SUBSTANCE: invention relates to the use of a compound of the formula (I), its tautomers or pharmaceutically acceptable salts for the prevention of hepatocellular carcinoma (HCC) induced by non-alcoholic steatohepatitis (hereinafter – NASH) in a subject.
EFFECT: prevention of NASH-induced hepatocellular carcinoma in a subject.
1 cl, 3 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2019 |
|
RU2815647C2 |
| NEW APPLICATIONS AND METHODS | 2017 |
|
RU2765804C2 |
| NALMEFEN, NALTREXONE OR DERIVATIVES THEREOF FOR USE IN TREATING (NON)-ALCOHOLIC STEATOHEPATITIS OR NON-ALCOHOLIC FATTY LIVER DISEASE | 2017 |
|
RU2717677C1 |
| TREATMENT OF LIVER, BILE DUCT AND PANCREATIC DISORDERS | 2017 |
|
RU2740913C2 |
| METHOD OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) WITH USING CYSTEAMINE PRODUCTS | 2008 |
|
RU2498795C2 |
| COMBINED THERAPY WITH APPLICATION OF CENICRIVIROC FOR FIBROSIS TREATMENT | 2015 |
|
RU2723559C2 |
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER | 2017 |
|
RU2717331C2 |
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER | 2017 |
|
RU2762193C2 |
| BIFIDOBACTERIUM LONGUM FOR TREATING OBESITY AND RELATED METABOLIC DISORDERS | 2016 |
|
RU2740096C2 |
| THERAPEUTIC AGENT FOR LIVER DISEASES | 2018 |
|
RU2723686C1 |
